Hepatic Encephalopathy Market To Find Better Growth with US$ 4,151.3 Million By 2026 | CAGR: 6.3%: Coherent Market Insights

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

The Global Hepatic Encephalopathy Market, by Drug Class (Antibiotic, Laxatives, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 2,547.8 million in 2018 and is estimated to exhibit a CAGR of 6.3% over the forecast period (2018-2026), as highlighted in a new report published by Coherent Market Insights.  

Get FREE Sample PDF Including COVID-19 Impact Analysis: https://www.coherentmarketinsights.com/insight/request-sample/2596

The increasing number of awareness programs related to hepatic encephalopathy (HE) is one of the major factors that is expected to augment the market growth over the forecast period. These programs focus on creating awareness among patients and healthcare professionals about different treatment options for HE and possible risk factors such as liver disease, hepatic cirrhosis, and hepatitis C. There are symptom, which needs to be noticed to avoid further risks. The symptoms of HE can vary from person to person and may depend on the severity of the liver disease and how well the patient is able to eliminate the liver toxins. In addition, HE adversely affects sleep hygiene.

Government healthcare regulatory bodies of various economies are engaged in the hepatic encephalopathy market, and focuses on research & development and awareness activities. For instance, ALIVER is the US$ 8.5 million project that was funded by the EU Horizon 2020 research program (Work started on ALIVER on January 1, 2017 and will end on September 30, 2020). The ALIVER consortium developed a novel and innovative liver dialysis machine that will aid the liver to naturally regenerate and to keep patients alive and healthy until a donated liver is available.

Moreover, the American Liver Foundation is engaged in facilitating, advocating, and promoting education, support, and research for the prevention, treatment, and cure of liver disease. The American Liver Foundation celebrates Hepatitis Awareness Month in May and urges everyone to learn what can be done to prevent the spread of hepatitis. Many forms of hepatitis are preventable and can be treated if detected early.

Browse 28 Market Data Tables and 26 Figures spread through 147 Pages and in-depth TOC on “Hepatic Encephalopathy Market, by Drug Class (Antibiotic, Laxatives, and Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Global Forecast to 2026”

To know the latest trends and insights related to global hepatic encephalopathy market, click the link below: https://bit.ly/35EQedZ

Furthermore, key players in the market are focused on adopting strategies such as product development and acquisitions, and also focuses on gaining product approvals to strengthen their market position, which is expected to drive growth of the market. For instance, in February 2015, Bausch Health Companies acquired Salix Pharmaceuticals for a total enterprise value of around US$ 14.5 billion. Through this acquisition, Salix’s market-leading gastrointestinal franchise is an ideal strategic fit for Valeant’s diversified portfolio of specialty products. For instance, in September 2016, ASKA received marketing and manufacturing approval for RIFXIMA from the Japanese regulatory authority indicated for the treatment of hyperammonemia in HE. On the basis of clinical data, the Japanese Clinical Practice Guidelines 2015 for Hepatic Cirrhosis included RIFXIMA as an effective drug for HE to be used in Japanese clinical practice.

Similarly, in April 2018, Ferring Pharmaceuticals Inc. announced that they agreed for the acquisition of Rebiotix Inc. This acquisition brings together two innovative healthcare companies which share a common commitment to exploring and understanding the human microbiome to develop new solutions for patients.

Furthermore, in September 2014, Lupin Limited and Salix Pharmaceuticals, Inc. entered into a definitive distribution agreement. According to this agreement, Salix Pharmaceuticals, Inc. granted Lupin Limited the exclusive right to market, distribute, and sell certain Salix products related to the hepatic encephalopathy in Canada.

Special Requirements?
We value your investment and offer customization as per your requirements.

Share your precise requirements @ https://www.coherentmarketinsights.com/insight/request-customization/2596

Key Takeaways of the Hepatic Encephalopathy Market:

• The global hepatic encephalopathy market is expected to exhibit a CAGR of 6.3% over the forecast period (2018-2026), attributed to increasing number of awareness programs related to Hepatic Encephalopathy (HE).
• On the basis of drug class, antibiotics segment accounted for major market share in 2017. Major pharmacological treatments for HE are non-absorbable disaccharides such as non-absorbable antibiotics. Rifaximin is the most potential antibiotic used as a therapy for HE. A significant benefit of Rifaximin is that it is minimally absorbed when taken orally—less than 0.4% of the drug is absorbed in patients with HE.
• On the basis of distribution channel, hospital pharmacies segment accounted for major market share in 2017. This is attributed to hospital pharmacies that act as a key channel in distribution of HE treatment medications.
• Key players operating in the global hepatic encephalopathy market include ASKA Pharmaceutical Co., Ltd., Cosmo Pharmaceuticals N.V., Lupin Limited, Kaleido Biosciences, Kannalife Sciences, Inc., Bausch Health Companies Inc., Ferring Pharmaceuticals Inc., Mallinckrodt Pharmaceuticals, Umecrine Cognition AB, and Norgine B.V., among others

Apply Promo Code “STAYHOME” And Get an Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/2596

About Us:

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.

To know more about us, please visit our website – www.coherentmarketinsights.com

Contact:

Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837

This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at contact@cdnnewswire.com.